Metabolic Category
THE APPETITE CRUSHER
TE-1; NS2330
Tesofensine is a triple monoamine reuptake inhibitor that was originally developed for Parkinson's and Alzheimer's. It blocks reuptake of dopamine, norepinephrine, and serotonin, powerfully reducing appetite and increasing energy expenditure. In trials it produced greater weight loss than any other single agent, making it one of the most effective compounds for obesity.
Research links are provided so readers can inspect the supporting evidence directly.
No. This profile records Tesofensine as not FDA approved and for research use only.
Review the regulatory and source details on this page for the current context.
No linked research sources are currently available on this guide.
Treat the profile as provisional until supporting sources are published.
Reported side effects of Tesofensine include Dry mouth, Insomnia, Increased heart rate, Elevated blood pressure, and Constipation.
They are reported or occasional reactions, not a prediction of what any one person will experience.
Tesofensine has an editorial safety grade of C (Moderate Safety).
Effective but can affect cardiovascular parameters. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.
Blocks DAT, NET, and SERT transporters
Increases monoamines in hypothalamic feeding centers
Enhances sympathetic activity and energy expenditure
Improves dopamine-mediated focus and motivation
Those with significant weight to lose · People who struggle with appetite control · Those who haven't responded to other weight loss drugs · Anyone wanting cognitive boost alongside weight loss
Market evidence
We found certificates from some of the Tesofensine vendors we track. Based on the certificates our crawler found; vendors may publish more than we index. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.
Certificate assessment
1 evaluated certificates
1 graded · 0 not graded · 0 in the A range.
Each result belongs to the named vendor’s certificate. Grades assess the document and its reported tests, not the vendor’s whole catalog or the safety of a product.
Automated checks can make mistakes. Open “Why this result?” for the reason and any review notice, and check the linked COA’s lot against your product. How grading works
1 evaluated record
Document grade
C10: No endotoxin (bacterial toxin) test is reported, and an injectable needs one, so the grade stops at D.
Document check: flag.
Lab record: matched.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
1001
| COA grade | Printed lab | Certificate | |||
|---|---|---|---|---|---|
| OmegaAmino Lot: 1001 | Document grade Why this result?C10: No endotoxin (bacterial toxin) test is reported, and an injectable needs one, so the grade stops at D. Document check: flag. Lab record: matched. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | Freedom Diagnostics | Jul 24, 2026 | No purity printed | View COA |
The clinic network
Request a free connection to a peptide clinic, by telehealth or in person. A licensed clinician decides whether any treatment is right for you. What peptide therapy involves
Triple-action peptide with 24% average weight loss in trials.
from $1.50/mg · 381 vendorsNº 003 / 006FDA-approved for weight loss. Patients lose 20%+ of their body weight.
from $0.95/mg · 305 vendorsNº 006 / 006Next-gen weight loss with dual hormone action
from $7/mg · 26 vendorsNº 002 / 006FDA-approved GLP-1 that produced 15% weight loss in trials.
from $0.10/mg · 148 vendorsNº 004 / 006FDA-approved for rare genetic obesity disorders
from $6/mg · 1 vendorNº 005 / 006Boost metabolism and burn fat without changing your diet
from $0.90/mg · 139 vendorsNº 001 / 006
